Noelia Tarazona received her MD from the University of Valencia in 2007. After completing her medical training in Oncology at the Hospital Clinico Universitario in Valencia (Spain) under the mentorship of Prof Andrés Cervantes, she completed postgraduate studies in Molecular Oncology in 2012, with special interest for translational research in gastrointestinal cancers. She is currently doing a Master´s Degree in Immuno-Oncology at the University of Navarra to improve her knowledge in this area.

She received an ESMO Translational Research Fellowship and joined the Gastrointestinal and Lymphoma Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2013 for a two-year fellowship under the supervision of Prof. David Cunningham and Prof. Nicholas Turner, working on several clinical research projects in early drug development and gastrointestinal cancers, specially focused on understanding the FGFR signalling pathway as therapeutic targets for breast and gastric cancer. From 2015, she gradually focused her work towards liquid biopsy and its role in providing information about the presence of minimal residual disease and tumour genotyping, identifying molecular mechanisms of resistance to treatment and potential therapeutic molecular targets for several types of cancer.

Her main interest is to determine the prognostic and predictive value of liquid biopsies in localised colorectal cancer patients and its integration in a multi-omic strategy through analyses of multiple sequential tumour and liquid biopsies. She is involved in the set-up of the CIBERONC (Center for the Biomedical Research Network in Oncology) Liquid Biopsy Working Module in Spain.

After receiving a Rio Hortega Grant awarded by the Instituto de Salud Carlos III in 2016, she is presently pursuing a PhD at INCLIVA Biomedical Research Institute (Spain); the focus of her research is to analyse the clinical impact at baseline, as well as the follow-up with serial monitoring of ctDNA from liquid biopsies and its inclusion into a muti-omic approach in localised colorectal cancer patients. The ultimate aim of her project is to improve the prognostic assessment, as a first step, to establish individualised therapy approach for this setting. In 2015, she received a grant for young oncologists awarded by the Mari Paz Jimenez Casado Foundation and she was selected to be a part of the 2018 ESMO Leaders Generation Programme.